 Abstract Alzheimer's disease, AD, is a progressive neurodegenerative disorder that affects millions worldwide. Despite recent advancements in research, there is currently no effective treatment available. This paper proposes a new approach to treating AD by using a nanoparticle drug delivery system called Transfer and Receptor Zinc RNA-aptamer, TR-ZRA. The system is designed to target the blood-brain barrier and deliver therapeutics to the brain. It is loaded with two components, a CD-22SHRNA plasmid to reduce the production of a protein associated with AD and A-beta aptomers to detect A-beta plaque levels. TR-ZRA was tested in mouse models of AD and found to improve cognitive function and reduce inflammation. Additionally, it was shown to increase the ability of microglia to clear A-beta from the brain. These results suggest that TR-ZRA could be used as a potential treatment for AD. This article was authored by Yanrong Su, Yufan Huang, Qin Jekou, and others. We are article.tv, links in the description below.